These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 29601411)

  • 1. Antihypertensive drug use in resistant and nonresistant hypertension and in controlled and uncontrolled resistant hypertension.
    de la Sierra A; Armario P; Oliveras A; Banegas JR; Gorostidi M; Vinyoles E; de la Cruz JJ; Segura J; Ruilope LM
    J Hypertens; 2018 Jul; 36(7):1563-1570. PubMed ID: 29601411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension.
    Azizi M; Perdrix L; Bobrie G; Frank M; Chatellier G; Ménard J; Plouin PF
    J Hypertens; 2014 Oct; 32(10):2038-44; discussion 2044. PubMed ID: 24983187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in Antihypertensive Medication Use Among US Patients With Resistant Hypertension, 2008 to 2014.
    Hwang AY; Dave C; Smith SM
    Hypertension; 2016 Dec; 68(6):1349-1354. PubMed ID: 27777360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan.
    Omboni S; Volpe M
    Adv Ther; 2019 Feb; 36(2):278-297. PubMed ID: 30591990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment.
    Omboni S; Kario K; Bakris G; Parati G
    J Hypertens; 2018 Apr; 36(4):720-733. PubMed ID: 29045341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial.
    Jo SH; Park SJ; Kim EJ; Kim SJ; Cho HJ; Song JM; Shin J; Park JJ; Shin JH; Han KR; Choi DJ
    Trials; 2018 Jun; 19(1):324. PubMed ID: 29925421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
    Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
    Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy.
    Tocci G; Paneni F; Passerini J; Volpe M
    Expert Opin Pharmacother; 2012 Dec; 13(18):2687-97. PubMed ID: 23170911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug therapy for the patient with resistant hypertension.
    Donazzan L; Ewen S; Papademetriou V; Linicus Y; Linz D; Böhm M; Mahfoud F
    Future Cardiol; 2015 Mar; 11(2):191-202. PubMed ID: 25760878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study.
    Ruilope LM; Schaefer A
    Contemp Clin Trials; 2011 Sep; 32(5):710-6. PubMed ID: 21586342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents.
    Hanselin MR; Saseen JJ; Allen RR; Marrs JC; Nair KV
    Hypertension; 2011 Dec; 58(6):1008-13. PubMed ID: 22042809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistant Hypertension: Which Agent?
    Prosser HCG; Azzam O; Schlaich MP
    Heart Lung Circ; 2018 Aug; 27(8):911-916. PubMed ID: 29526418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Davis BR; Piller LB; Cutler JA; Furberg C; Dunn K; Franklin S; Goff D; Leenen F; Mohiuddin S; Papademetriou V; Proschan M; Ellsworth A; Golden J; Colon P; Crow R;
    Circulation; 2006 May; 113(18):2201-10. PubMed ID: 16651474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT.
    Bangalore S; Davis BR; Cushman WC; Pressel SL; Muntner PM; Calhoun DA; Kostis JB; Whelton PK; Probstfield JL; Rahman M; Black HR;
    Am J Med; 2017 Apr; 130(4):439-448.e9. PubMed ID: 27984005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
    Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension.
    Chrysant SG
    Expert Rev Cardiovasc Ther; 2009 Aug; 7(8):887-95. PubMed ID: 19673666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cochrane in context: pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh RS
    Evid Based Child Health; 2014 Sep; 9(3):581-3. PubMed ID: 25236306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of amlodipine/olmesartan ± hydrochlorothiazide in patients uncontrolled on prior calcium channel blocker or angiotensin II receptor blocker monotherapy.
    Neutel J; Shojaee A; Maa JF
    Adv Ther; 2012 Jun; 29(6):508-23. PubMed ID: 22773358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.